Development of Measures to Determine Successful Hearing Health Care Outcomes

by: Iola Bonggay

The National Institutes of Health, otherwise known as NIH, is a federal government agency operating within the United States Department of Health and Human Services that is largely responsible for financially supporting all of the country's health-related and biomedical research studies.

The programs and grants of the NIH are all geared towards the achievement of its overall agency mission which is to "seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce the burdens of illness and disability."

In accordance with this mission, the National Institutes of Health has recently collaborated with the National Institute on Deafness and Other Communication Disorders (NIDCD) in an attempt to constitute the Development of Measures to Determine Successful Hearing Health Care Outcomes Program.

The program essentially intends to solicit applications that seek to identify the variables that contribute to successful hearing health care outcomes in adults with hearing loss, as well as to be able to create and evaluate the clinical measures involved within those said variables.

In the context of this announcement, HHC refers to hearing health outcomes while HL refers to hearing loss. Furthermore, the initiatives associated with HHC includes hearing screening/assessment, the acquisition of an appropriate hearing aid( HA), and several other non-medical interventions for HL.

  (continued...)

Development of Measures to Determine Successful Hearing Health Care Outcomes
  Page 2

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Small Business Innovation Research Phase IIB Bridge Awards
In line with this mission, the NIH has recently constituted the Small Business Innovation Research Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization Program.

---

Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
The USFA has recently formed a collaboration with the National Institutes of Health to establish the Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.

---

Cancer Education Grants Program
The National Cancer Institute has developed the Cancer Education Grants Program wherein it seeks to financially support innovative educational efforts that would contribute to the reduction of cancer incidences, morbidity and mortality rates; as well as the improvement of the quality of life of surviving cancer patients.

---

Development of Therapeutics and Diagnostics for Biodefense Program
The National Institutes of Health, in partnership with the National Institute of Allergy and Infectious Diseases(NIAID), has established the Development of Therapeutics and Diagnostics for Biodefense Program in an attempt to seek research proposals that desire to support the development of lead candidate diagnostics or therapeutics against NIAID Category A, B, or C priority agents.

---